H

Herantis Pharma Oyj
OMXH:HRTIS

Watchlist Manager
Herantis Pharma Oyj
OMXH:HRTIS
Watchlist
Price: 1.555 EUR -5.76% Market Closed
Market Cap: 31.3m EUR
Have any thoughts about
Herantis Pharma Oyj?
Write Note

Herantis Pharma Oyj
Investor Relations

Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.

Show more

Earnings Calls

No Earnings Calls Available

Management

Dr. Antti Vuolanto D.Sc. (Tech)
Chief Executive Officer
No Bio Available
Ms. Tone Kvale
Chief Financial Officer
No Bio Available
Dr. Henri J. Huttunen Ph.D.
Chief Scientific Officer
No Bio Available
Mr. Jani Koskinen
Head of CMC
No Bio Available
Ms. Outi Lahdenperä M.D., Ph.D.
Chief Medical Ofcer
No Bio Available
Dr. Charlotte Videbaek M.D.
Clinical Consultant
No Bio Available

Contacts

Address
ETELA-SUOMEN
Espoo
Bertel Jungin Aukio 1
Contacts
+35892221195.0
herantis.com